Patents by Inventor Kyle Seamon

Kyle Seamon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cascade/dCas3 Complementation Assays for In Vivo Detection of Nucleic Acid-Guided Nuclease Edited Cells
    Publication number: 20220267747
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Application
    Filed: May 10, 2022
    Publication date: August 25, 2022
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11359187
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: June 14, 2022
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Cascade/dCas3 Complementation Assays for In Vivo Detection of Nucleic Acid-Guided Nuclease Edited Cells
    Publication number: 20220177865
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 9, 2022
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Engineered enzymes
    Patent number: 11345903
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: May 31, 2022
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11286471
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: March 29, 2022
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Cascade/dCas3 Complementation Assays for In Vivo Detection of Nucleic Acid-Guided Nuclease Edited Cells
    Publication number: 20220073892
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Application
    Filed: November 15, 2021
    Publication date: March 10, 2022
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • NOVEL MAD NUCLEASES
    Publication number: 20220049233
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Application
    Filed: November 3, 2021
    Publication date: February 17, 2022
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11198857
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: December 14, 2021
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Mad nucleases
    Patent number: 11193115
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: December 7, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • Cascade/dCas3 Complementation Assays for In Vivo Detection of Nucleic Acid-Guided Nuclease Edited Cells
    Publication number: 20210355467
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 18, 2021
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Mad nucleases
    Patent number: 11174471
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: November 16, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • NOVEL MAD NUCLEASES
    Publication number: 20210324355
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Application
    Filed: March 12, 2021
    Publication date: October 21, 2021
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • NOVEL MAD NUCLEASES
    Publication number: 20210301270
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Application
    Filed: March 12, 2021
    Publication date: September 30, 2021
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11104890
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: August 31, 2021
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • MAD nucleases
    Patent number: 11085030
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: August 10, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • MAD nucleases
    Patent number: 11053485
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: July 6, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • NOVEL MAD NUCLEASES
    Publication number: 20210198641
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Application
    Filed: March 12, 2021
    Publication date: July 1, 2021
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • NOVEL MAD NUCLEASES
    Publication number: 20210171923
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Application
    Filed: October 29, 2020
    Publication date: June 10, 2021
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • ENGINEERED ENZYMES
    Publication number: 20210155912
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Application
    Filed: November 19, 2020
    Publication date: May 27, 2021
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11008557
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: May 18, 2021
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon